Discovery of A Small Molecule non-IMiD Degrader of ZBTB7A for the Treatment of β-hemoglobinopathies

Jun Liu, Ziyang Shen, Shin‐Young Park, Yanhua Dong, Na Yu, Jing Zeng, Lee Hannah, Braden Pate, Sophia Adamia, Kim Vanuytsel, Junyan Zhang, Shankai Wu, A.g. Herman, Shiva Moein, Wenhui Liu, Miao Liu, Chong Gao, Xi Tian, Zhaoji Liu, Junsu Kwon, Kunhua Qin, Christoph Budjan, Po‐Shen Ko, C. Shao, Chaitanya K. Jaladanki, Jiajia Li, Eunsong Lee, Bo Liu, Sean R. Stowell, John Manis, David G. Justus, Gerd A. Blobel, Hongbo R. Luo, Roger Belizaire, Yi Zheng, Sahand Hormoz, Sarah Nikiforow, José A. Cancelas, Hao Fan, Daniel E. Bauer, Daniel G. Tenen, Li ChaibioRxiv 2025 · DOI

TL;DR

Researchers have discovered SH6, a novel small molecule that degrades the ZBTB7A protein, a key repressor of fetal hemoglobin (HbF). This degradation effectively reactivates HbF production in erythroid cells, showing promise as a new therapeutic strategy for sickle cell disease and β-thalassemia, with a favorable safety profile observed in preclinical models.

What Problem Does This Paper Address?

Sickle cell disease (SCD) and transfusion-dependent β-thalassemia are severe inherited blood disorders caused by defects in the β-globin gene, leading to insufficient or faulty hemoglobin production. Current treatments, such as hydroxyurea, transfusions, and bone marrow transplantation, often have limitations in effectiveness, tolerability, or accessibility. A promising therapeutic avenue is to reactivate the production of fetal hemoglobin (HbF), which can compensate for the defective adult hemoglobin. The transcription factor ZBTB7A plays a crucial role in suppressing HbF production during the transition from fetal to adult hemoglobin. Therefore, finding ways to inhibit ZBTB7A's function is a key target for developing new treatments.

Methods

The study employed a multi-pronged approach to discover and characterize SH6:

  • In Silico Docking Analysis: Computational modeling was used to predict how SH6 might bind to ZBTB7A, identifying potential binding sites and key interactions.
  • Cellular Assays:
    • HUDEP-2 cells: An immortalized cell line was used to study erythroid differentiation and the effects of SH6 on ZBTB7A protein levels and HbF induction. CRISPR-Cas9 was used to generate ZBTB7A and CRBN knockout cell lines to confirm the mechanism of action.
  • Primary CD34+ cells: Hematopoietic stem and progenitor cells from healthy donors and patients with SCD and β-thalassemia were differentiated into erythroid cells to assess SH6's efficacy in more relevant models.
  • Cellular Thermal Shift Assay (CETSA): This technique was used to confirm direct binding between SH6 and ZBTB7A by measuring changes in protein stability upon drug treatment.
  • Molecular Biology Techniques:
    • Western Blotting (WB): Used to detect and quantify protein levels of ZBTB7A.
  • Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR): Used to measure mRNA levels of globin genes (HBG1/2, HBB, HBE).
  • High-Performance Liquid Chromatography (HPLC): Used to separate and quantify globin chains, including HbF.
  • Flow Cytometry: Used to analyze HbF expression and erythroid differentiation markers.
  • In Vivo Xenotransplantation Model: Humanized mice (NBSGW mice engrafted with human CD34+ cells) were used to evaluate SH6's efficacy and toxicity in a living system.

Datasets

Not explicitly detailed as "datasets" in the traditional machine learning sense. The study utilized:

  • Cell lines: HUDEP-2 cells (immortalized human erythroid progenitor cell line).
  • Primary cells: CD34+ hematopoietic stem and progenitor cells from healthy donors, sickle cell disease patients, and β-thalassemia patients.
  • Patient-derived induced pluripotent stem cells (iPSCs): From sickle cell disease patients.
  • Humanized mouse models: NBSGW mice engrafted with human CD34+ cells.

Key Insights and Ideas

  • Targeting ZBTB7A for HbF Induction: The study validates ZBTB7A as a critical target for reactivating fetal hemoglobin, a key strategy for treating β-hemoglobinopathies.
  • SH6 as a Novel Molecular Degrader: SH6 is identified as a small molecule that doesn't fit the typical immunomodulatory drug (IMiD) class but still functions as a molecular glue, recruiting ZBTB7A for degradation via the CRBN/CRL4 complex. This offers a potentially different safety profile compared to IMiDs.
  • CRBN-Dependent Mechanism: The degradation of ZBTB7A and subsequent HbF induction by SH6 are shown to be dependent on the E3 ubiquitin ligase CRBN, highlighting the specific molecular pathway involved.
  • Synergy with Hypomethylating Agents: SH6 demonstrates synergistic effects with hypomethylating agents like DAC, suggesting combination therapies could be more potent.
  • Preservation of Erythroid Differentiation: A crucial finding is that SH6 induces HbF without impairing normal erythroid differentiation or causing globin chain imbalance, addressing a key concern for potential therapies.
  • Favorable In Vivo Profile: The xenotransplantation model showed that SH6 can induce HbF in vivo with minimal toxicity, supporting its potential for clinical development.

Key Results

  • ZBTB7A Degradation: SH6 treatment led to a significant decrease in ZBTB7A protein levels in various cell models, confirmed by mass spectrometry and Western blotting.
  • HbF Induction: SH6 treatment resulted in a dose-dependent increase in fetal hemoglobin (HbF) levels in HUDEP-2 cells, healthy donor CD34+ derived erythroid cells, and patient-derived SCD and β-thalassemia erythroid cells.
  • In HUDEP-2 cells, SH6 achieved comparable or superior HbF induction compared to existing agents like hydroxyurea, pomalidomide, and decitabine at nanomolar doses.
  • In vivo, SH6 treatment in humanized mice showed a small but significant induction of HbF in bone marrow-derived human erythroid cells.
  • Mechanism Confirmation: SH6's effect on HbF induction was abrogated in CRBN knockout HUDEP-2 cells, confirming the CRBN-dependent mechanism.
  • Minimal Toxicity: In vitro and in vivo studies indicated a favorable toxicity profile for SH6, with stable body weights, normal organ histology, and preserved erythroid differentiation and enucleation in treated mice.

Limitations and Future Work

  • Structural Basis: The precise structural basis for SH6-mediated recruitment of ZBTB7A to CRBN requires further investigation, potentially using cryo-electron microscopy or X-ray crystallography.
  • Comprehensive Toxicology: While minimal toxicity was observed, more comprehensive toxicology studies are needed, especially in tissues where ZBTB7A has critical roles beyond erythropoiesis (e.g., lymphoid specification, tumor suppression).
  • In Vivo Combination Therapies: The synergy observed between SH6 and DAC in vitro needs to be evaluated in vivo using xenograft models or patient-derived organoids.
  • Patient Variability: Expanding preclinical studies across diverse patient backgrounds is necessary to assess variability in response to SH6 treatment.

Summary updated

Abstract

Abstract Sickle cell disease and β-thalassemia, two major β-hemoglobinopathies, pose significant clinical challenges globally. Current treatments often face limitations in efficacy and tolerability. The transcription factor ZBTB7A has emerged as a promising therapeutic target for reactivating fetal hemoglobin expression. Here, we report the discovery and characterization of SH6, a small molecule non-IMiD degrader of ZBTB7A. SH6 induces fetal hemoglobin in erythroid cell lines in a CRBN and ZBTB7A-dependent manner, and it is capable of inducing fetal hemoglobin expression in healthy donor, SCD and β-thalassemia patient CD34+ cell derived erythroid cells. The efficacy of SH6 is confirmed in a xenotransplantation humanized mouse model. SH6 outperforms currently available therapeutic agents in vitro , and shows synergy with hypomethylating agents. SH6 exhibits a favorable in vivo toxicity profile. Our findings establish SH6 as a promising therapeutic lead candidate for further optimization towards clinical development for treatment of sickle cell disease and β-thalassemia.
BibTeX
@misc{liu2025discovery,
  author = {Jun Liu and Ziyang Shen and Shin‐Young Park and Yanhua Dong and Na Yu and Jing Zeng and Lee Hannah and Braden Pate and Sophia Adamia and Kim Vanuytsel and Junyan Zhang and Shankai Wu and A.G. Herman and Shiva Moein and Wenhui Liu and Miao Liu and Chong Gao and Xi Tian and Zhaoji Liu and Junsu Kwon and Kunhua Qin and Christoph Budjan and Po‐Shen Ko and C. Shao and Chaitanya K. Jaladanki and Jiajia Li and Eunsong Lee and Bo Liu and Sean R. Stowell and John Manis and David G. Justus and Gerd A. Blobel and Hongbo R. Luo and Roger Belizaire and Yi Zheng and Sahand Hormoz and Sarah Nikiforow and José A. Cancelas and Hao Fan and Daniel E. Bauer and Daniel G. Tenen and Li Chai},
  title = {{Discovery of A Small Molecule non-IMiD Degrader of ZBTB7A for the Treatment of β-hemoglobinopathies}},
  year = {2025},
  doi = {10.1101/2025.09.17.676148},
  howpublished = {bioRxiv},
}
Figure